CureVac

CureVac would be the next the largest biotech company in Germany. CureVac N.V. is a German biotech business that develops messenger RNA (mRNA) therapeutics. CureVac was regarded as a ray of hope for the development of a German vaccine at the start of the COVID-19 epidemic. The federal government put $300 million into the enterprise. First, the CureVac vaccine was delayed due to minor issues, while Pfizer-backed BioNTech created the highly effective BNT162b2. However, by mid-2021, it was clear that the CureVac-vaccine was only 47 percent effective and was still a long way from approval.

The company's primary goal is to create vaccinations for infectious diseases as well as medications to treat cancer and uncommon diseases. In addition to the German government, CureVac has partnerships with Boehringer Ingelheim, Sanofi Pasteur, Johnson & Johnson, Genmab, the Bill & Melinda Gates Foundation, Eli Lilly and Company, GlaxoSmithKline, the Coalition for Epidemic Preparedness Innovations, and the International AIDS Vaccine Initiative.

CureVac demonstrated the potential of mRNA to treat diseases and generate vaccines with a single discovery. CureVac, which was created in 2000, is the world's first startup to successfully harness mRNA for medical applications. It is at the forefront of developing a whole new class of medications based on messenger RNA (mRNA). The main idea is to employ this molecule as a data carrier for information, allowing the body to manufacture its own active chemicals to treat various ailments.

Founded: 2000
Headquarters: Tübingen, Germany
Website: https://www.curevac.com/